Oligonucleotide CDMO Market

The global oligonucleotide CDMO market is projected to reach USD 6.73 billion in 2029 from USD 2.51 billion in 2024, with a CAGR of 21.8%. Rising outsourcing of development and manufacturing to CDMOs and growing focus on precision/personalized medicine are some of the factors driving the market's growth. Furthermore, the rising focus on the development and commercialization of oligo-based therapeutics are increasing the demand for oligonucleotide CDMO, further boosting the market's growth in coming years.

The market for oligonucleotide CDMO market is consolidated, with key players strategizing to capture the majority of the market. Prominent players in the oligonucleotide CDMO market are Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), Agilent Technologies, Inc. (US), Kaneka Eurogentec S.A. (Belgium), Ajinomoto Co., Inc. (Japan), Aurigene Pharmaceutical Services Ltd. (India), Bachem (Switzerland),  Syngene International Limited (India), PolyPeptide Group (Switzerland), WuXi AppTec (China), EUROAPI (France),  Eurofins Scientific (Luxembourg), GenScript (US), and Danaher Corporation (US) among others. The market players have adopted various strategies such as the development of advanced products, partnerships, contracts, expansions, and acquisitions to strengthen their position in the oligonucleotide CDMO market.

To know about the assumptions considered for the study download the pdf brochure

Bachem is one of key players and well-established companies operating in the Oligo CDMO market. The company is mainly focused on commercial manufacturing of oligonucleotide API and is expected to grow in the oligonucleotide contract manufacturing market. The company focuses on oligonucleotides and peptides molecules. This makes the company a specialized CDMO in oligonucleotide manufacturing. Bachem collaborates with major pharma biotech companies focusing on oligonucleotide and peptide-based therapeutics development to maintain and enhance its position in the market. The company’s manufacturing capabilities, technologically advanced facilities, and regulatory compliance attract end users. For example, in April 2022, Bachem and Lilly signed a collaboration to develop and manufacture oligonucleotide-based drug substances.

Agilent Technologies, Inc. is one of the key players operating in the oligonucleotide Contract Development and Manufacturing Organization (CDMO) market. Agilent offers a wide range of CDMO services for oligonucleotides, such as custom oligonucleotide synthesis, process development and optimization, analytical method development and validation, and large-scale manufacturing for clinical and commercial applications. The company’s comprehensive service portfolio, manufacturing capabilities, strong brand recognition and geographic presence are some of the key factors for its strong strategic position in the market.

Thermo Fisher Scientific Inc. is one of the top key players operating in the oligonucleotide Contract Development and Manufacturing Organization (CDMO) market, leveraging its advanced capabilities in scalable oligonucleotide synthesis and end-to-end manufacturing solutions. Its integration of solid-phase synthesis, proprietary purification technologies, and automated high-throughput systems ensures production consistency for therapeutic oligonucleotides such as siRNAs, and ASOs, among others. Thermo Fisher Scientific leads the oligonucleotide CDMO market through its comprehensive service portfolio and robust technological infrastructure. The company’s OligoPerfect Primer Designer platform enables customized oligonucleotide design, accelerating development timelines for antisense oligonucleotides (ASOs) and siRNA therapeutics. Additionally, its deep expertise in analytical development, including advanced HPLC, LC-MS, and CE technologies, ensures precise characterization and stringent quality control of oligonucleotides at every production stage. Additionally, the company’s strong geographic reach allows it to maintain its position in the market.

Related Reports:

Oligonucleotide CDMO Market by Service (Contract Manufacturing (Clinical, Commercial), Development), Type (ASO, SiRNA, (CPG Oligos, gRNA)), Application (Therapeutic, Research, Diagnostic), End User (Pharma, Biotech) - Global Forecast to 2029

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]